Header Logo

Connection

Lynn Morris to Peptide Fragments

This is a "connection" page, showing publications Lynn Morris has written about Peptide Fragments.
Connection Strength

1,582
  1. High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J Med Virol. 2006 Oct; 78(10):1262-8.
    View in: PubMed
    Score: 0,270
  2. Genetic characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006 Dec 5-20; 356(1-2):95-105.
    View in: PubMed
    Score: 0,268
  3. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide. AIDS Res Hum Retroviruses. 2005 Sep; 21(9):776-83.
    View in: PubMed
    Score: 0,250
  4. Sensitivity of HIV type 1 subtype C isolates to the entry inhibitor T-20. AIDS Res Hum Retroviruses. 2004 May; 20(5):477-82.
    View in: PubMed
    Score: 0,228
  5. HIV-1 clade C escapes broadly neutralizing autologous antibodies with N332 glycan specificity by distinct mechanisms. Retrovirology. 2016 08 30; 13(1):60.
    View in: PubMed
    Score: 0,134
  6. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med. 2015 Nov; 21(11):1332-6.
    View in: PubMed
    Score: 0,126
  7. High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. Virology. 2009 May 10; 387(2):414-26.
    View in: PubMed
    Score: 0,080
  8. A reliable phenotype predictor for human immunodeficiency virus type 1 subtype C based on envelope V3 sequences. J Virol. 2006 May; 80(10):4698-704.
    View in: PubMed
    Score: 0,065
  9. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol. 2003 Apr; 77(7):4449-56.
    View in: PubMed
    Score: 0,053
  10. HIV Superinfection Drives De Novo Antibody Responses and Not Neutralization Breadth. Cell Host Microbe. 2018 10 10; 24(4):593-599.e3.
    View in: PubMed
    Score: 0,039
  11. Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. J Virol. 2009 Feb; 83(3):1240-59.
    View in: PubMed
    Score: 0,020
  12. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol. 2008 Dec; 82(23):11651-68.
    View in: PubMed
    Score: 0,019
  13. The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection. J Virol. 2008 Feb; 82(4):1860-9.
    View in: PubMed
    Score: 0,018
  14. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol. 2002 Mar; 76(5):2233-44.
    View in: PubMed
    Score: 0,012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.